← Back to Search

pegsitacianine for Peritoneal Carcinomatosis

Phase 2
Waitlist Available
Research Sponsored by OncoNano Medicine, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial is testing a new cancer-detecting agent that may help improve outcomes for patients with peritoneal carcinomatosis.

Eligible Conditions
  • Peritoneal Carcinomatosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinically Significant Events (CSE)
Secondary outcome measures
Pegsitacianine fluorescence and imaging performance
Pegsitacianine safety

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fluorescence imaging with pegsitacianineExperimental Treatment1 Intervention
1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
pegsitacianine
2021
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

OncoNano Medicine, Inc.Lead Sponsor
3 Previous Clinical Trials
222 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are being welcomed into this clinical trial?

"Sixty individuals are needed to complete this study's protocol. These research subjects must meet the required inclusion criteria and can come from different parts of the country, like Winston-Salem, North carolina or Houston, Texas."

Answered by AI

What are the potential risks associated with pegsitacianine?

"While there is some data indicating that pegsitacianine is safe, as this is only a Phase 2 trial, efficacy has not been established yet. Therefore, it received a score of 2."

Answered by AI

Could you tell me how many hospitals have been selected to test this new medical treatment?

"Currently, this trial is taking place in Winston-Salem, Houston and Pittsburgh as well as 5 other locations. If you are considering enrolling, please note that it may be advantageous to select the clinical site closest to your home."

Answered by AI

Are there any patients that have not yet been enrolled in this experiment?

"Yes, according to the listing on clinicaltrials.gov, this study is open for enrollment. The trial was first announced on 11/30/2021 with the most recent update being on 9/19/2022. This research is looking for 60 individuals total at 5 sites."

Answered by AI
~15 spots leftby Mar 2025